Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial

Comparing the time from enrolment to the primary endpoint of either a CD4 cell count ≤ 350 cells/mm3  or initiation of HAART for any reason